Statistical Thinking for Non-Statisticians in Drug Regulation (2nd ed, 2014)

sampson2010 · 发表于 2015-5-27 17:43:36

注册后推荐绑定QQ，之后方才可以使用下方的“用QQ帐号登录”。

您需要登录才可以下载或查看，没有账号？立即注册

x

本帖最后由 sampson2010 于 2015-5-27 18:45 编辑

Title: Statistical Thinking for Non-Statisticians in Drug Regulation
$ J' Y& Y. l0 h6 c9 uAuthor(s): Richard Kay/ _/ L5 d3 h6 {+ f9 O1 q. G
Publisher: Wiley, O! ]8 s' `. b, j9 z5 Q# A
Year: 2014 3 f/ }/ w3 t* H! A
Edition: 2
1 q, ^2 x8 l( g# L9 |0 MLanguage: English 9 N3 c' U2 C) Z3 U2 q- `
Pages: 3689 {: y/ Y c( B
ISBN: 111847094X, 9781118470947# d1 a+ T5 C/ g( E$ Y- a
Size: 2 MB (2224739 bytes) : q7 c, M3 T' F/ r* D8 e* T
Extension: pdf

Description

Statistical Thinking for Non-Statisticians in Drug Regulation, Second Edition, is a need-to-know guide to understanding statistical methodology, statistical data and results within drug development and clinical trials.

It provides non-statisticians working in the pharmaceutical and medical device industries with an accessible introduction to the knowledge they need when working with statistical information and communicating with statisticians. It covers the statistical aspects of design, conduct, analysis and presentation of data from clinical trials in drug regulation and improves the ability to read, understand and critically appraise statistical methodology in papers and reports. As such, it is directly concerned with the day-to-day practice and the regulatory requirements of drug development and clinical trials.

Fully conversant with current regulatory requirements, this second edition includes five new chapters covering Bayesian statistics, adaptive designs, observational studies, methods for safety analysis and monitoring and statistics for diagnosis.

Authored by a respected lecturer and consultant to the pharmaceutical industry, Statistical Thinking for Non-Statisticians in Drug Regulation is an ideal guide for physicians, clinical research scientists, managers and associates, data managers, medical writers, regulatory personnel and for all non-statisticians working and learning within the pharmaceutical industry.

Table of Contents

Preface to the second edition xv

Preface to the first edition xvii

Abbreviations xxi

1 Basic ideas in clinical trial design 1

1.1 Historical perspective 1

1.2 Control groups 2

1.3 Placebos and blinding 3

1.4 Randomisation 3

1.5 Bias and precision 9

1.6 Between- and within-patient designs 11

1.7 Crossover trials 12

1.8 Signal noise and evidence 13

1.9 Confirmatory and exploratory trials 15

1.10 Superiority equivalence and non-inferiority trials 16

1.11 Data and endpoint types 17

1.12 Choice of endpoint 18

2 Sampling and inferential statistics 23

2.1 Sample and population 23

2.2 Sample statistics and population parameters 24

2.3 The normal distribution 28

2.4 Sampling and the standard error of the mean 31

2.5 Standard errors more generally 34

3 Confidence intervals and p-values 38

3.1 Confidence intervals for a single mean 38

3.2 Confidence interval for other parameters 42

3.3 Hypothesis testing 45

4 Tests for simple treatment comparisons 56

4.1 The unpaired t-test 56

4.2 The paired t-test 57

4.3 Interpreting the t-tests 60

4.4 The chi-square test for binary data 61

4.5 Measures of treatment benefit 64

4.6 Fisher’s exact test 69

4.7 Tests for categorical and ordinal data 71

4.8 Extensions for multiple treatment groups 75

5 Adjusting the analysis 78

5.1 Objectives for adjusted analysis 78

5.2 Comparing treatments for continuous data 78

5.3 Least squares means 82

5.4 Evaluating the homogeneity of the treatment effect 83

5.5 Methods for binary categorical and ordinal data 86

5.6 Multi-centre trials 87

6 Regression and analysis of covariance 89

6.1 Adjusting for baseline factors 89

6.2 Simple linear regression 89

6.3 Multiple regression 91

6.4 Logistic regression 94

6.5 Analysis of covariance for continuous data 94

6.6 Binary categorical and ordinal data 101

6.7 Regulatory aspects of the use of covariates 103

6.8 Baseline testing 105

7 Intention-to-treat and analysis sets 107

7.1 The principle of intention-to-treat 107

7.2 The practice of intention-to-treat 110

7.3 Missing data 113

7.4 Intention-to-treat and time-to-event data 118

7.5 General questions and considerations 120

8 Power and sample size 123

8.1 Type I and type II errors 123

8.2 Power 124

8.3 Calculating sample size 127

8.4 Impact of changing the parameters 130

8.5 Regulatory aspects 132

8.6 Reporting the sample size calculation 134

9 Statistical significance and clinical importance 136

9.1 Link between p-values and Confidence intervals 136

9.2 Confidence intervals for clinical importance 137

9.3 Misinterpretation of the p-value 139

9.4 Single pivotal trial and 0.05 140

10 Multiple testing 142

10.1 Inflation of the type I error 142

10.2 How does multiplicity arise? 143

10.3 Regulatory view 144

10.4 Multiple primary endpoints 145

10.5 Methods for adjustment 149

10.6 Multiple comparisons 152

10.7 Repeated evaluation over time 153

10.8 Subgroup testing 154

10.9 Other areas for multiplicity 156

11 Non-parametric and related methods 158

11.1 Assumptions underlying the t-tests and their extensions 158

11.2 Homogeneity of variance 158

11.3 The assumption of normality 159

11.4 Non-normality and transformations 161

11.5 Non-parametric tests 164

11.6 Advantages and disadvantages of non-parametric methods 168

11.7 Outliers 169

12 Equivalence and non-inferiority 170

12.1 Demonstrating similarity 170

12.2 Confidence intervals for equivalence 172

12.3 Confidence intervals for non-inferiority 173

12.4 A p-value approach 174

12.5 Assay sensitivity 176

12.6 Analysis sets 178

12.7 The choice of Δ 179

12.8 Biocreep and constancy 184

12.9 Sample size calculations 184

12.10 Switching between non-inferiority and superiority 186

13 The analysis of survival data 189

13.1 Time-to-event data and censoring 189

13.2 Kaplan-Meier curves 190

13.3 Treatment comparisons 193

13.4 The hazard ratio 196

13.5 Adjusted analyses 199

13.6 Independent censoring 202

13.7 Sample size calculations 203

14 Interim analysis and data monitoring committees 205

14.1 Stopping rules for interim analysis 205

14.2 Stopping for efficacy and futility 206

14.3 Monitoring safety 210

14.4 Data monitoring committees 211

15 Bayesian statistics 215

15.1 Introduction 215

15.2 Prior and posterior distributions 215

15.3 Bayesian inference 219

15.4 Case study 221

15.5 History and regulatory acceptance 222

15.6 Discussion 224

16 Adaptive designs 225

16.1 What are adaptive designs? 225

16.2 Minimising bias 228

16.3 Unblinded sample size re-estimation 232

16.4 Seamless phase II/III studies 234

16.5 Other types of adaptation 236

16.6 Further regulatory considerations 238

17 Observational studies 241

17.1 Introduction 241

17.2 Guidance on design conduct and analysis 247

17.3 Evaluating and adjusting for selection bias 249

17.4 Case–control studies 257

18 Meta-analysis 261

18.1 Definition 261

18.2 Objectives 263

18.3 Statistical methodology 264

18.4 Case study 270

18.5 Ensuring scientific validity 271

18.6 Further regulatory aspects 275

19 Methods for the safety analysis and safety monitoring 277

19.1 Introduction 277

19.2 Routine evaluation in clinical studies 279

19.3 Data monitoring committees 289

19.4 Assessing benefit–risk 290

19.5 Pharmacovigilance 299

20 Diagnosis 304

20.1 Introduction 304

20.2 Measures of diagnostic performance 304

20.3 Receiver operating characteristic curves 308

20.4 Diagnostic performance using regression models 310

20.5 Aspects of trial design for diagnostic agents 312

20.6 Assessing agreement 313

21 The role of statistics and statisticians 316

21.1 The importance of statistical thinking at the design stage 316

21.2 Regulatory guidelines 317

21.3 The statistics process 321

21.4 The regulatory submission 327

21.5 Publications and presentations 328

References 331

Index 339

Author Information

Richard Kay, Consultant in Statistics for the Pharmaceutical Industry, Great Longstone, Derbyshire, UK

Statistical Thinking for Non-Statisticians in Drug Regulation (2nd ed, 2014).pdf (2.12 MB, 下载次数: 44)

来自群组: RGCE

账号		自动登录	找回密码
密码			立即注册

[分享] Statistical Thinking for Non-Statisticians in Drug Regulation (2nd ed, 2014)

注册后推荐绑定QQ，之后方才可以使用下方的“用QQ帐号登录”。

本帖被以下淘专辑推荐: